Thermo Fisher Scientific (TMO) Stock
Global leader in laboratory instruments and consumables. Here's the price, business snapshot, and what's worth knowing about Thermo Fisher Scientific in August 2026.
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It’s Moving
Thermo Fisher’s portfolio reset and stronger outlook are keeping the 2026 upside story alive.
- Thermo Fisher completed the $1.075 billion sale of its microbiology business, sharpening the company’s portfolio and adding capital that can be recycled into higher-growth diagnostics and life sciences areas.
- Management recently lifted 2026 guidance after second-quarter results topped expectations, reinforcing the view that demand is holding up better than feared despite a choppy macro backdrop.
- Fresh clinical diagnostics momentum, including FDA-cleared testing platforms and new workflow tools, is helping offset slower parts of the business and supporting analyst confidence in the 2026 setup.
Thermo Fisher’s portfolio reset and stronger outlook are keeping the 2026 upside story alive.
- Thermo Fisher completed the $1.075 billion sale of its microbiology business, sharpening the company’s portfolio and adding capital that can be recycled into higher-growth diagnostics and life sciences areas.
- Management recently lifted 2026 guidance after second-quarter results topped expectations, reinforcing the view that demand is holding up better than feared despite a choppy macro backdrop.
- Fresh clinical diagnostics momentum, including FDA-cleared testing platforms and new workflow tools, is helping offset slower parts of the business and supporting analyst confidence in the 2026 setup.
Sixth Month Growth Performance
When is the next earnings date for Thermo Fisher Scientific (TMO)?
Thermo Fisher Scientific’s next earnings date is expected around October 28, 2026, based on the company’s recent reporting pattern. The report should cover Q3 2026. The exact date has not yet been formally confirmed, so it remains an estimate until the company announces it.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Thermo Fisher Scientific's stock, with a target price of $636.43.
Financial Health
Thermo Fisher Scientific is performing well with strong revenue and cash flow, indicating solid financial stability.
Dividend
Thermo Fisher Scientific's dividend yield of 0.3% is low, indicating limited income for investors. If you invested $1000, you would be paid $3 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
